

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Horizon Health Limited
諾輝健康

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6606)

INSIDE INFORMATION
DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS;
POSTPONEMENT OF BOARD MEETING;
AND
SUSPENSION OF TRADING

This announcement is published by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that the Company will not be able to publish the annual results for the year ended December 31, 2023 (the “**2023 Annual Results**”) in accordance with Rules 13.49(1) and (2) of the Listing Rules, as the Company is still in the process of addressing certain concerns raised by Deloitte Touche Tohmatsu, the auditor of the Company (the “**Auditor**”) as mentioned in the letters to the Board and/or audit committee of the Company (the “**Audit Committee**”). The Auditor (a) raised certain concerns in relation to the (i) validity of certain sales transactions of ColoClear and commercial substance and business rationale of the relevant sales models; (ii) validity of certain sales transactions of Pupu Tube or UU Tube; and (iii) validity of certain selling and marketing expenses and commercial substance and business rationale of the relevant underlying marketing activities; and hence (b) considered necessary for the Audit Committee to conduct an independent investigation. In line with the Auditor’s request, the Audit Committee has engaged third-party specialists (the “**Investigators**”) to conduct an independent investigation. The Company is working closely with the Investigators, the Audit Committee and the Auditor and in the process of providing the necessary information and documents, as well as maintaining active dialogues with the Investigators, the Audit Committee and the Auditor to resolve all outstanding issues. However, the expected date of the publication of the 2023 Annual Results will need to be further discussed and determined, and will be announced as and when appropriate.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2023 Annual Results on a date not later than three months after the end of the financial year of the Company, i.e. on or before March 31, 2024. In light of the aforementioned circumstances, there will be a delay in the Company's publication of the 2023 Annual Results, which will constitute a non-compliance of Rule 13.49(1) of the Listing Rules.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and (2) of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the Auditor (so far as the information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Company for the year ended December 31, 2023 at this stage as such management accounts may not accurately reflect the financial performance and position of the Company.

POSTPONEMENT OF BOARD MEETING

Reference is made to the announcement of the Company dated March 18, 2024 in relation to the meeting of the Board to be held on Thursday, March 28, 2024 for the purpose of, among other matters, considering and approving the annual results of the Group for the year ended December 31, 2023 and its publication, and transacting any other business. As the 2023 Annual Results will not be available for publication by March 28, 2024, the meeting of the Board for the purpose of, among other matters, considering and approving the 2023 Annual Results and its publication, will be postponed.

SUSPENSION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer's securities if an issuer fails to publish periodic financial information in accordance with the Listing Rules, and the suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information. Trading in the shares of the Company on the Stock Exchange was halted with effect from 9:00 a.m. on March 28, 2024 and will continue to be suspended, pending the publication of the 2023 Annual Results.

The Company wishes to emphasise that the operations of the Group remain normal. The Company will publish further announcement(s) in due course to inform the Shareholders and its potential investors of (i) the date of the meeting of the Board to consider and approve the 2023 Annual Results; (ii) the date of the release of the 2023 Annual Results; and (iii) any material development.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
New Horizon Health Limited
Mr. YeQing ZHU
Chairman

Hong Kong, March 28, 2024

As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU and Dr. Donald Kwok Tung LI as independent non-executive Directors.